BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10197806)

  • 1. IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
    Nagayama H; Takahashi S; Takahashi T; Ogami K; Ikebuchi K; Tojo A; Tani K; Asano S
    Bone Marrow Transplant; 1999 Jan; 23(2):183-5. PubMed ID: 10197806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful graft-versus-leukemia effect of second bone marrow transplantation on relapsed leukemia cutis that was refractory to intensive chemotherapy and donor lymphocyte transfusions in a patient with acute monocytic leukemia.
    Ashida T; Kawanishi K; Ariyama T; Hamasaki H; Maeda Y; Tsubaki K; Kanamaru A
    Int J Hematol; 2000 Jun; 71(4):385-8. PubMed ID: 10905060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
    Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA
    Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
    Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Complete autologous bone marrow recovery after allogeneic stem cell transplantation in a child with acute monoblastic leukemia].
    Balwierz W; Chełmecka-Hanusiewic L; Klekawka T; Wójcik B; Kowalczyk JR; Ksiazek T
    Przegl Lek; 2010; 67(6):425-6. PubMed ID: 21344774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
    Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
    Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recurrent spontaneous regression of aleukemic leukemia cutis in a girl with acute monocytic leukemia].
    Kajiwara R; Goto H; Yanagimachi M; Kuroki F; Fujii H; Takahashi H; Yokota S
    Rinsho Ketsueki; 2006 Aug; 47(8):764-9. PubMed ID: 16986716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
    Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
    Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation.
    Imoto S; Murayama T; Gomyo H; Mizuno I; Sugimoto T; Nakagawa T; Koizumi T
    Bone Marrow Transplant; 2000 Oct; 26(7):809-10. PubMed ID: 11042667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation.
    Huang X; Guo N; Ren H; Zhang Y; Gao Z; Lu D
    Chin Med J (Engl); 2003 May; 116(5):736-41. PubMed ID: 12875692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
    Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S
    Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.